Oxyargin

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxyargin (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate, the active ingredient in Oxyargin, is an opioid analgesic presented as an oral tablet for oral use. It treats moderate to severe pain in adult patients and helps reduce opioid‑induced constipation.
GNH India supplies Oxyargin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Generics [uk] Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxyargin combines an opioid agonist with a peripheral antagonist to manage pain while limiting constipation. It is indicated for:

Chronic severe pain: provides effective analgesia while mitigating opioid‑induced constipation.
Cancer‑related pain: manages moderate to severe pain in oncology patients.
Opioid‑induced constipation: naloxone component reduces constipation without compromising analgesia.

How It Works

Oxycodone binds to central μ‑opioid receptors, inhibiting nociceptive transmission and producing analgesia. Naloxone, poorly absorbed orally, antagonizes peripheral μ‑receptors in the gastrointestinal tract, thereby counteracting opioid‑induced constipation while allowing oxycodone’s central analgesic effect to persist.

Side Effects

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Dizziness: transient light‑headedness.
Somnolence: increased sleepiness.
Headache: mild cranial discomfort.
Dry mouth: reduced salivation.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that may be life‑threatening.
Severe hypotension: marked drop in blood pressure.
Opioid dependence or withdrawal: signs of addiction or abrupt cessation symptoms.
Allergic reaction: rash, itching, swelling, or anaphylaxis.
Adrenal insufficiency: fatigue, weakness, low blood pressure.
Severe gastrointestinal obstruction: abdominal pain and vomiting.

Precautions & Warnings

Before prescribing Oxyargin, clinicians should consider several safety measures.

Pain assessment: confirm severity and need for opioid therapy.
Respiratory monitoring: watch for signs of depression, especially in opioid‑naïve patients.
Hepatic/renal function: adjust use if liver or kidney impairment is present.
Gastrointestinal obstruction: avoid in patients with known blockage or severe constipation.
Elderly patients: start at lower doses and monitor closely for sedation.
Store at ambient temperature: keep in the original pack, protect from moisture.

Avoid Interactions

Oxyargin may interact with other medicines, requiring careful review.

Major Interactions (Avoid)

CNS depressants (benzodiazepines, barbiturates, alcohol): risk of profound sedation and respiratory depression.
Strong CYP3A4 inhibitors (ketoconazole, erythromycin): increase oxycodone plasma levels.
Monoamine oxidase inhibitors (MAOIs): potential for serotonin syndrome.

Moderate Interactions (Monitor Closely)

CYP3A4 inducers (rifampin, carbamazepine): may reduce analgesic effect.
Diuretics: can exacerbate hypotension.
Antihistamines and antidepressants (SSRIs): may increase sedation or serotonin-related effects.

Frequently Asked Questions

Oxyargin is a combination of oxycodone and naloxone used to treat moderate to severe pain, such as chronic non‑cancer pain, cancer‑related pain, and to reduce opioid‑induced constipation in adult patients.

Oxycodone activates μ‑opioid receptors in the central nervous system to block pain signals, while naloxone, which is minimally absorbed when taken orally, blocks peripheral μ‑receptors in the gut, helping to prevent constipation without reducing the analgesic effect.

The dose of Oxyargin is individualized by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and overall health status. No fixed regimen is provided here; the prescriber determines the appropriate strength and frequency.

Oxyargin is generally contraindicated during pregnancy and lactation because opioids can affect fetal development and may be excreted in breast milk. Women who are pregnant, planning pregnancy, or nursing should discuss alternative therapies with their healthcare provider.

To request Oxyargin, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with single‑agent opioids, Oxyargin adds naloxone to mitigate opioid‑induced constipation while preserving analgesia. This can reduce the need for additional laxatives, but the combination still carries typical opioid risks such as respiratory depression and dependence.

Store Oxyargin tablets at ambient temperature, below 25 °C, in the original container to protect from moisture and light. Keep out of reach of children and do not use if the packaging is damaged.

Oxyargin is taken orally, usually with water. It should be swallowed whole and not crushed or chewed, as altering the tablet can affect the balance between oxycodone and naloxone and increase the risk of side effects.

The most serious risks include respiratory depression, severe hypotension, opioid dependence or withdrawal, and rare allergic reactions such as anaphylaxis. Patients should seek immediate medical attention if they experience shallow breathing, extreme drowsiness, fainting, or signs of an allergic response.

Oxyargin should be avoided in patients with known hypersensitivity to oxycodone or naloxone, those with significant respiratory compromise, untreated severe asthma, gastrointestinal obstruction, or in individuals taking MAO inhibitors. It is also contraindicated in pregnant or breastfeeding women unless clearly indicated by a physician.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.